Delivering Innovative Thinking to Advance Early Phase Research
Pressure to contain the rising costs of drug development continues to force biopharmaceutical sponsors to find ways to inject efficiencies into the research process. As a result, early phase study design and its effect on predicting late phase research outcomes is critical.
Azelix early phase teams provide innovations in translational medicine techniques – bench to bedside strategies – supporting success early on. Azelix offers comprehensive services for the outset, incorporating comprehensive services to ensure success.
Termed Translational or “bench to bedside” medicine, the concept forms the initial basis for evidence-based practice and clinical guidelines. In the case of drug discovery and development, translational research typically refers to the translation of non-human research finding, from the laboratory and from animal studies, into therapies for patients. Azelix Early Phase uses many facets of translational medicine to facilitate the interaction between basic research and clinical medicine to design and conduct clinical trials including use of biomarker endpoints, bioanalytical methods, adaptive trial design and collaborative scientific teams over multiple disciplines.
This thoughtful design of studies in the Early Phase translates to efficiencies through-out late phase studies, affecting success rates of bringing promising compounds to a successful approval status.